Kornimate/medical-research-clean huggingface dataset:
co-operative training for stroke rehabilitation

Conditions: CO-OP; Attention Control

Summary: cognitive impairments occur frequently after stroke, and are associated with significant long-term activities of daily living (adl) disability and poor quality of life. this research study will undertake an innovative approach addressing cognitive impairments, by examining a new patient-centered functionally-relevant rehabilitation intervention that teaches individuals with cognitive impairments to manage their deficits to reduce adl disability.

cognitive impairments are characterized by problems sustaining attention in distracting conditions, shifting attention between different task demands, and using working memory to consistently execute intended actions, and as a result limit the ability to execute routine adls. presently there are no interventions that have demonstrated robust effectiveness in reducing disability among individuals with cognitive impairments after stroke. recent findings suggest that individuals with cognitive impairments may experience adl disability in part because they have difficulty engaging in, and benefiting from rehabilitation programs as they are currently delivered. in other words, individuals with cognitive impairment, due to the nature of their impairments, have difficulty learning and applying adaptive strategies as they are currently provided during traditional rehabilitation training. therefore, interventions that train individuals with cognitive impairments a new way to learn and apply adaptive strategies may help them benefit from rehabilitation programs and reduce long-term disability. cognitive orientation to daily occupation performance (co-op) is a strategy training approach that trains individuals to identify problems in the performance of daily activities, develop strategies to address these problems, and monitor their own performance in the course of their daily routines. therefore, co-op teaches individuals to "take charge" of their rehabilitation, and develop adaptive behaviors to "work around" cognitive impairments to meet their goals. the proposed project examines whether co-op facilitates reductions in adl disability and improvements in rehabilitation engagement among individuals with cognitive impairments after acute stroke.

Eligibility criteria:
inclusion criteria: * primary diagnosis of acute stroke * admission to acute inpatient rehabilitation * impairment in cognitive functions (quick executive interview ≥ 3) exclusion criteria: * dementia diagnosis (as indicated in the medical record) * severe aphasia as indicated by score ≥ 2 on the boston diagnostic aphasia examination (3rd edition) severity rating scale (bdae-3) * current major depressive disorder (unless treated and in partial remission), bipolar or any other psychotic disorder (primary care evaluation of mental disorders) * drug or alcohol abuse within 3 months (mini-international neuropsychiatric interview) * anticipated length of stay less than 5 days

Keywords: stroke rehabilitation cognition intervention strategy training
correlation between cyriax's functional examination and ultrasound examination in patients with shoulder pain

Conditions: Shoulder Pain

Summary: shoulder problems cause substantial disability in daily living, work, leisure activity, and exercise. the presence of shoulder problem such as rotator cuff pathology reported was highly predictive of impaired health-related quality of life. many tests were used for physical examination of the shoulder. the reliability and validity of the tests have been studied before. however, a systemic review concluded that there was conflicting evidence in reliability of each or combined tests. functional examination of the shoulder by cyriax is composed of a series of tests to evaluate a shoulder problem. it includes three arm elevation, three tests for glenohumeral joints, and six resisted tests. as far as the investigators know, correlation of cyriax functional examination with the ultrasonographic findings has never been reported before. therefore, the aim of this study is to compare the clinical diagnosis by cyriax's functional examination with ultrasound findings in patients with shoulder pain.

there are two groups with fifty patients in each group. first group is patients who have unilateral or bilateral shoulder pain from the outpatient clinic of department of physical medicine and rehabilitation in shin kong wu ho-su memorial hospital. the other group is control group who has no shoulder problems. both groups will receive cyriax's functional examination of the shoulder after history taking, and will be examined by shoulder ultrasound in one week.

Eligibility criteria:
inclusion criteria: study group: 1. patients with unilateral or bilateral shoulder pain with unknown causes; 2. age≥ 20 years old. control group: 1. patients without unilateral or bilateral shoulder pain; 2. age≥ 20 years old. exclusion criteria: 1) chronic inflammatory joint disease, infections or tumors of the shoulder, previous fracture or surgery of shoulder, and referred pain from cervical origin or visceral organs.

Keywords: cyriax's functional examination ultrasound correlation resisted test
efficacy of prostate seed implantation for local control of early stage prostate cancer

Conditions: Prostate Cancer

Summary: the primary goal of this project is to evaluate the efficacy of prostate seed implantation for the treatment of early stage prostate cancer for patients treated at summa health system/akron city hospital and salem community hospital.

charts of early stage prostate cancer patients receiving prostate seed implants with or without external beam radiotherapy and/or hormonal therapy will be reviewed and abstracted. the abstracted data will include pathology reports including gleason score and t stage, psa, treatment assignment and dosimetry parameters including dose and percent compliant with established criteria based on guidelines established by the american brachytherapy society. a database will be developed for capture of the abstracted data. outcomes will be determined based on psa levels at 2 and 5 years after prostate seed implantation. the role of hormonal therapy with prostate seed implantation and outcomes will be evaluated. the outcomes will be compared to national statistics.

Eligibility criteria:
inclusion criteria: * prostate seed implantation for the treatment of early stage prostate cancer

Keywords: seed implantation
study on the functionality, safety and reliability of a robotic prosthesis for the lower limb at the transfemoral level

Conditions: Amputation; Traumatic Amputation; Leg Injury; Lower Limb Injury

Summary: the goal of this multicenter interventional pilot is to verify the functionality of a prosthesis for trans-femoral amputees. the main question it aims to answer are: * is to verify the technical functionality, safety and reliability of the propulsive lower limb prosthesis prototype, with active ankle, so as to provide indications regarding the technical and functional developments to be implemented in the finalization of the device. * provide an indication of the functional effectiveness of the device and its satisfaction by patients. participants will perform: * walking tests inside parallel bars on flat and/or inclined terrain; * walking tests on treadmill; * stair climbing/descent tests.


Eligibility criteria:
inclusion criteria: * trans femoural amputation * medicare functional classification levels k3-k4 * expert prosthesis wearer (more than one year) * electronic knee prostheses user * energy-release prosthetic foot user exclusion criteria: * relevant medical comorbidities * heart device wearers (pmk or aicd) * cognitive impairment * anxious or depressed illness

Keywords: lower limb transfemoral
evaluation of the impact of chemotherapy on body odor in adolescents and young adults in oncology

Conditions: Solid Tumor, Adult; Solid Tumor, Childhood; Chemotherapy Effect

Summary: the appearance of unpleasant body odors in adolescent young adult (aya) wille be evaluated undergoing chemotherapy


Eligibility criteria:
inclusion criteria: * patients aged between 15 and 25 years; * new patients treated at the curie institute and hospitalized in the aja oncology department; * patient undergoing chemotherapy administered intravenously; * solid tumors. exclusion criteria: * patient undergoing oral chemotherapy; * persons deprived of their liberty or under guardianship (including guardianship); * inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.
study on evaluation of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for prostate cancer

Conditions: Prostatic Neoplasms; Bone Density

Summary: the purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.


Eligibility criteria:
inclusion criteria: * prostate cancer patients aged between 50-80 who is having or will have adt. baseline bmd in between -2 standard deviation (sd) and mean of that among young adults. exclusion criteria: * patients with renal or liver problems, on calcium or other bisphosphonate therapy within six months before enrolling into the study. patients who have: * serum creatinine levels \>212 µmol/l (2.4 mg/dl). * creatinine clearance \<50 ml/min. * wbc \<4.0x109/l, hgb \<10 g/dl, platelets \<140x109/l. patients with known hypersensitivity to bisphosphonates. patients with history of diseases with influence on bone metabolism, such as page's disease of bone, primary hyperparathyroidism or osteoporosis.

Keywords: prostate cancer bone mineral density
study of targeted therapies for the treatment of adult participants with active psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: psoriatic arthritis (psa) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. symptoms can get worse and go away for periods of time. this study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. the therapies being assessed in this sub-study are risankizumab and lutikizumab. participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. around 120 participants will be enrolled in the study at approximately 40 sites worldwide. there may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). participants will attend regular visits during the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: * participant is willing and able to comply with procedures required in the master protocol and substudies. * participant has a documented clinical diagnosis of psa with symptom onset at least 6 months prior to the screening visit and fulfillment of the classification criteria for psoriatic arthritis (caspar) at screening visit. * participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the screening visit and baseline. * participant has active plaque pso and/or a documented history of plaque pso. * participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of psa exclusion criteria: * participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation). * participants with the following chronic or active infections: are infected with human immunodeficiency virus (hiv), active hepatitis b virus (hbv) or hepatitis c virus(hcv) infection, active tuberculosis(tb) * active skin disease other than psoriasis (pso) which could interfere with the assessment of pso. * history of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (psa) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).
adipose mesenchymal stem cells (amsc) for treatment of ulcerative colitis

Conditions: Ulcerative Colitis (UC)

Summary: ulcerative colitis is a form of inflammatory bowel disease characterized by diffuse inflammation of the colonic mucosa. it affects the rectum and extends proximally along a variable length of the colon. ulcerative colitis is a chronic condition with a relapsing remitting course. mesenchymal stem cells (mscs) are a subset of adult stem cells residing in many tissues, including bone marrow (bm), adipose tissue, umbilical cord blood. recent experimental findings have shown the ability of mscs to home to damaged tissues and to produce paracrine factors with anti-inflammatory properties, potentially resulting in reduction of inflammation and functional recovery of the damaged tissues. the purpose of our study is to evaluate safety and efficacy of the intracolonic injection by using a colonoscope of allogeneic adipose mscs in patients with moderate active ulcerative colitis.


Eligibility criteria:
inclusion criteria: * male or female, 18-65 years old * diagnosis of ulcerative colitis diagnosed at least 6 months earlier * moderate or severe activity defined by a mayo score * no serious infection, chronic diseases, diabetes and tuberculosis * unefficient by using 5-asa, glucocorticoid or azathioprine * written informed consents were obtained from all subjects * capable of good communication with researchers and follow the entire test requirements * negative pregnancy test for women of childbearing potential (from menarche to menopause) exclusion criteria: * pregnant or breastfeeding women or cognitively impaired adults * history of malignant disease * infectious colitis * patients with known allergies to culture medium * patients having participated in clinical trials with any investigational drug within 1 month prior to enrolment in this study * patients with suspicion of crohn's enterocolitis, indeterminate colitis, ischaemic colitis, radiation colitis, diverticular disease associated colitis, or microscopic colitis * patients with previous colectomy * positive to one or more of the infectious disease panel * treatment with surgery or biological treatment (infliximab or adamizumab) or cyclosporine or tacrolimus or mycophenolate in the 8 weeks prior to inclusion in the study * presence of severe concomitant diseases * patients with clostridium difficult or cytomegalovirus infection

Keywords: ulcerative colitis (uc) mesenchymal stem cells(msc)
intraperitoneal hyperthermic chemotherapy in epithelial ovarian carcinoma

Conditions: Epithelial Ovarian Carcinoma; Figo Stage IIIC

Summary: phase ii to study results and morbidity of intra peritoneal hyper-thermic chemotherapy as consolidation therapy in patients with figo stage iiic epithelial ovarian carcinoma treated by surgery and a total of 6 cycles of platinum based chemotherapy. a second look operation is performed after treatment; during this second look secondary cytoreductive surgery is accepted without bowel resection.if none or milimetric peritoneal disease is obseved an intraperitoneal chemotherapy is achieve


Eligibility criteria:
inclusion criteria: epithelial ovarian carcinoma previous surgery + 6 cycles platinum based chemotherapy - exclusion criteria: * patients asa 3 patients with no residual tumor at first operation negative microscopic second look

Keywords: previous treatment surgery + 6 cycles of platinum based chemotherapy
ultrabrief pulsewidth electroconvulsive therapy (ect)

Conditions: Major Depressive Disorder

Summary: electroconvulsive therapy (ect) remains essential to contemporary psychiatric practice and is one of the safest and most effective treatments available for depression. despite modern advances in pharmacotherapy, about 15-20 per cent of all hospitalised patients receive treatment with ect. its use, however, is limited by concerns over associated cognitive side effects. recent research has suggested that using an ultrabrief pulsewidth with ect may greatly reduce cognitive side effects, while maintaining efficacy (sackeim et al 2008). preliminary results were positive for unilateral ect, however, suggest that for bilateral ect, dosing may need to be adjusted to preserve efficacy while reducing side effects. this study will examine the relative cognitive side effects and efficacy of right unilateral and bilateral ect given with a standard pulsewidth or an ultrabrief pulsewidth. some participants will also receive an mri scan before and after ect.


Eligibility criteria:
inclusion criteria: * subjects meet criteria for a dsm-iv-tr major depressive episode * total madrs score \>/= 25 * age \>/= 18 years * educated or working in an english medium setting exclusion criteria: * diagnosis (as defined by dsm-iv-tr) of any psychotic disorder (lifetime with exception of major depressive episode with psychotic features); rapid cycling bipolar disorder, eating disorder (current or within the past year); obsessive compulsive disorder (lifetime); post-traumatic stress disorder (current or within the past year). * history of drug or alcohol abuse or dependence (as per dsm-iv-tr) in the last 6 months (except nicotine and caffeine). * ect in last 3 months * subject requires an urgent clinical response due to inanition, psychosis or high suicide risk * unable to give informed consent * score \< 24 on mini mental state examination
effects of vitamin d status and multiple mega-dose supplementation on health care disparities in perioperative patients with hepatocellular carcinoma receiving hepatectomy

Conditions: Hepatocellular Carcinoma; Liver Function; Postoperative Complications

Summary: high concentrations of parathyroid hormone (pth) are common in patients with hepatocellular carcinoma (hcc). this study is aimed to investigate effects of vitamin d status and its multiple mega-dosage supplementation on pth and clinical outcomes in hcc patients before and after hepatectomy. it's a single-center, prospective, parallel, double-blind, placebo-controlled study for 120 eligible subjects. the subjects will receive consecutively 3-day intervention treatments from 7th day before surgery. 30-day postoperative mortality, postoperative complications, and laboratory data will be evaluated.


Eligibility criteria:
inclusion criteria: * 1. ≥ 20-year hcc subjects receiving laparoscopic hepatectomy * 2.sign the informed consent exclusion criteria: * 1. using estrogen drugs, bisphosphonates, or drugs for bone disease. * 2. consume calcium tablets within 2 weeks before operation * 3. sarcoidosis, multiple myeloma * 4. pregnant women or plan to become pregnant within 3 months after surgery * 5. autoimmune hepatitis (aih) * 6. early liver recurrence * 7. used to participate in other clinical trials

Keywords: vitamin d supplementation hepatectomy perioperative
senl-t7 car-t cells for treatment of relapsed or refractory cd7+ lymphoma

Conditions: Lymphoma, T-Cell

Summary: this study is an open and prospective clinical study, taking patients with relapsed or refractory cd7+ lymphoma as the test subjects, in order to evaluate the safety and efficacy of senl-t7 car-t for patients with cd7+ lymphoma.

main research purposes: to evaluate the safety and efficacy of senl-t7 car-t for relapsed or refractory cd7+ lymphoma secondary research purpose: to investigate the cytokinetic characteristics of senl-t7 car-t for relapsed or refractory cd7+ lymphoma.

Eligibility criteria:
inclusion criteria: * 1. diagnosed as relapsed or refractory lymphoma; 2. tumor cells express cd7 (express cd7 by flow cytometry or immunohistochemistry); 3. the expected survival period is greater than 12 weeks; 4. kps or lansky score ≥60; 11 5. age 2-70 years old; 6. hgb≥70g/l (can be transfused); 7. indoor blood oxygen saturation\> 90%; 8. total bilirubin does not exceed 3 times the upper limit of normal value, and ast and alt do not exceed 5 times the upper limit of normal value; 9. the subject or guardian understands and signs the informed consent form; exclusion criteria: * 1. one of the following cardiac criteria: atrial fibrillation; myocardial infarction within the past 12 months; prolonged qt synthesis syndrome or secondary qt prolongation is at the discretion of the investigator. echocardiography lvsf\<30% or lvef\< 50%; clinically significant pericardial effusion; cardiac insufficiency nyha (new york heart association) iii or iv (the absence of this symptom confirmed by echocardiography within 12 months after treatment); 2. there is active gvhd; 3. have a history of severe pulmonary dysfunction diseases; 4. merge other malignant tumors in advanced stage; 5. combined with severe infection or persistent infection and cannot be effectively controlled; 6. combined with severe autoimmune disease or congenital immunodeficiency; 7. active hepatitis (hepatitis b virus deoxyribonucleic acid \[hbvdna\] or hepatitis c virus ribonucleic acid \[hcvrna\] test positive); 8. human immunodeficiency virus (hiv) infection or syphilis infection or htlv infection; 9. there is a history of severe allergies to biological products (including antibiotics); 10. clinically significant viral infection, or uncontrollable viral reactivation, including ebv (epstein-barr virus), cmv (cytomegalovirus), adv (adenovirus), bkv, hhv(human herpesvirus)-6; 11. there are central nervous system disorders, such as uncontrolled epilepsy, cerebrovascular ischemia/hemorrhage, dementia, cerebellar diseases, etc.; 12. female patients are pregnant and lactating, or have a pregnancy plan within 12 months; 13. circumstances that the researcher believes may increase the risk of the subject or interfere with the results of the test.
efficacy study of new therapeutic schedules in naive hepatitis c virus (hcv) patients infected with genotype 3 (hcv-3)

Conditions: Chronic Hepatitis

Summary: the study aimed at evaluating whether current 24 weeks length of combination treatment is appropriate or not for patients with hcv genotype 3 infection.

patients are randomized to standard length of treatment or to a variable duration: 12 weeks for patients with undetectable hcvrna at week 4 or 24 or 36 weeks for those with detectable hcv rna at week 4.

Eligibility criteria:
inclusion criteria: * naive hcv patients * hcvrna positive * normal tsh * ana \<1:160 exclusion criteria: * portal hypertension * renal failure * hbsag or hiv * alcohol consumption \>30 g/day * active iv drug use * chronic systemic diseases

Keywords: genotype 3 combination treatment short treatment